SEC Info℠

Home

Search

My Interests

Help

Sign In

Please Sign In

Dr Reddys Laboratories Ltd – ‘6-K’ for 12/31/16 – ‘EX-99.2’

On:  Tuesday, 1/10/17, at 10:28am ET   ·   For:  12/31/16   ·   Accession #:  1193125-17-6469   ·   File #:  1-15182

Previous ‘6-K’:  ‘6-K’ on 1/10/17 for 11/30/16   ·   Next:  ‘6-K’ on / for 1/24/17   ·   Latest:  ‘6-K’ on / for 4/25/24

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

 Text Wildcards:  ? (any letter/digit),  * (many).  Search Logic:  for Documents:  & (and),  | (or);  for Text:  | (anywhere),  "(&)" (near).  Details... 

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 1/10/17  Dr Reddys Laboratories Ltd        6-K        12/31/16    3:72K                                    Donnelley … Solutions/FA

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Report by a Foreign Private Issuer                  HTML     11K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML      9K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML      8K 

Exhibit 99.2

Dr. Reddy’s Laboratories Limited to present at the

J.P. Morgan 35^th Annual Healthcare Conference

Hyderabad, India and Princeton, NJ, USA. January 9^th, 2017 — Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that the Company will present at the J.P. Morgan 35^th Annual Healthcare Conference on Tuesday, January 10^th, 2017, in San Francisco.

The presentation is scheduled to begin at 2:30 p.m. PST [4:00 a.m. IST on January 11^th, 2017].

Presentation material will be available on the Company’s website www.drreddys.com

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, Russia & CIS and India. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.

The company assumes no obligation to update any information contained herein.